0HIY
vs
S&P 500
0HIY
S&P 500
Over the past 12 months, 0HIY has underperformed S&P 500, delivering a return of -63% compared to the S&P 500's +27% growth.
Stocks Performance
0HIY vs S&P 500
Performance Gap
0HIY vs S&P 500
Performance By Year
0HIY vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Atara Biotherapeutics Inc
Glance View
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in South San Francisco, California and currently employs 578 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). The Company’s pipeline products include Tab-cel, ATA188, ATA2271, ATA3271 and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is a T-cell immunotherapy for the treatment of multiple sclerosis.
